Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Surfactants: their critical role in enhancing drug delivery to the lungs
Division of Pharmaceutics, College of Pharmacy, University of Texas at Austin.
Department of Pulmonary Care, College of Medicine, University of Texas Health Science Center at San Antonio.
Division of Pharmaceutics, College of Pharmacy, University of Texas at Austin.
2011 (English)In: Therapeutic delivery, ISSN 2041-5990, E-ISSN 2041-6008, Vol. 2, no 5, 623-641 p.Article in journal (Refereed) Published
Abstract [en]

For local lung conditions and diseases, pulmonary drug delivery has been widely used for more than 50 years now. A more recent trend involves the pulmonary route as a systemic drug-delivery target. Advantages such as avoidance of the gastrointestinal environment, different enzyme content compared with the intestine, and avoidance of first-pass metabolism make the lung an alternative route for the systemic delivery of actives. However, the lung offers barriers to absorption such as a surfactant layer, epithelial surface lining fluid, epithelial monolayer, interstitium and basement membrane, and capillary endothelium. Many delivery strategies have been developed in order to overcome these limitations. The use of surfactants is one of these approaches and their role in enhancing pulmonary drug delivery is reviewed in this article. A systematic review of the literature relating to the effect of surfactants on formulations for pulmonary delivery was conducted. Specifically, research reporting enhancement of in vivo performance was focused on. The effect of the addition of surfactants such as phospholipids, bile salts, non-ionic, fatty acids, and liposomes as phospholipid-containing carriers on the enhancement of therapeutic outcomes of drugs for pulmonary delivery was compiled. The main use attributed to surfactants in pulmonary drug delivery is as absorption enhancers by mechanisms of action not yet fully understood. Furthermore, surfactants have been used to improve the delivery of inhaled drugs in various additional strategies discussed herein.

Place, publisher, year, edition, pages
2011. Vol. 2, no 5, 623-641 p.
National Category
Pharmaceutical Sciences Other Health Sciences
Research subject
Health Science
Identifiers
URN: urn:nbn:se:ltu:diva-64668DOI: 10.4155/tde.11.15PubMedID: 22833979Scopus ID: 2-s2.0-79956132295OAI: oai:DiVA.org:ltu-64668DiVA: diva2:1119617
Available from: 2017-07-04 Created: 2017-07-04 Last updated: 2017-07-05Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Morales, Javier O.
In the same journal
Therapeutic delivery
Pharmaceutical SciencesOther Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf